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The receptor for advanced glycation end products (RAGE) is a
pattern-recognition receptor and its engagement by ligands such
as high mobility group box 1 (HMGB1) is implicated in tumor
growth and metastasis. Low molecular weight heparin (LMWH)
has an antagonistic effect on the RAGE axis and is also reported
to exert an antitumor effect beyond the known activity of antico-
agulation. However, the link between the anti-RAGE and antitu-
mor activities of LMWH has not yet to be fully elucidated. In this
study, we investigated whether LMWH could inhibit tumor cell
proliferation, invasion, and metastasis by blocking the RAGE axis
using in vitro and in vivo assay systems. Stably transformed
HT1080 human fibrosarcoma cell lines were obtained, including
human full-length RAGE-overexpressing (HT1080RAGE), RAGE
dominant-negative, intracellular tail-deleted RAGE-overexpressing
(HT1080dnRAGE), and mock-transfected control (HT1080mock) cells.
Confocal microscopy showed the expression of HMGB1 and RAGE
in HT1080 cells. The LMWH significantly inhibited HMGB1-
induced NFjB activation through RAGE using an NFjB-dependent
luciferase reporter assay and the HT1080 cell lines. Overexpres-
sion of RAGE significantly accelerated, but dnRAGE expression
attenuated HT1080 cell proliferation and invasion in vitro, along
with similar effects on local tumor mass growth and lung metas-
tasis in vivo. Treatment with LMWH significantly inhibited the
migration, invasion, tumor formation, and lung metastasis of
HT1080RAGE cells, but not of HT1080mock or HT1080dnRAGE cells. In
conclusion, this study revealed that RAGE exacerbated the
malignant phenotype of human fibrosarcoma cells, and that this
exacerbation could be ameliorated by LMWH. It is suggested that
LMWH has therapeutic potential in patients with certain types of
malignant tumors. (Cancer Sci 2013; 104: 740–749)
R eceptor for advanced glycation end products is a multili-gand pattern-recognition receptor, having an extracellular
region with one V-type and two C-type immunoglobulin-like
domains, one transmembrane region, and a short C-terminal
intracellular stretch.(1,2) The V domain of RAGE is critical for
the binding of distinct ligands, such as AGE,(1,2) S100
proteins,(3,4) b-amyloid,(5,6) Mac1 ⁄CD11b,(7) lipopolysaccha-
rides,(8) phosphatidylserine,(9) and HMGB1.(10–12) The interac-
tion between RAGE and these ligands has been implicated in
proinflammatory reactions, diabetic vascular complications,
neurodegenerative disorders, and cancer.(1,13,14) The ligation of
RAGE is reported to cause the activation of multiple intracel-
lular signaling pathways, including Cdc42 ⁄Rac1, p38 MAP
kinase,(15) PKC,(16) and NFjB,(17) as well as the production of
reactive oxygen species. The biological outcomes are also
known to be divergent among cell types or under different
conditions. Concerning malignant tumors, the HMGB1–RAGE
axis is reported to be involved in tumor growth, invasion, and
metastasis.(10,18) RAGE expression has been documented in
human malignancies of the stomach,(19) colon and rectum,(20)
prostate,(21) lung,(20) breast,(20) and bone.(22)
Soft tissue sarcomas are rare malignant tumors arising from
mesenchymal tissues. Multiagent chemotherapy has improved
both the survival rate and limb function in patients with certain
mesenchymal malignant tumors, such as osteosarcoma(23) and
Ewing’s sarcoma.(24) Despite advances in chemotherapy regi-
mens, however, high-grade soft tissue sarcoma remains a fatal
disease with frequent distant metastases.(25–27) To improve the
prognosis of high-grade soft tissue sarcoma, new therapeutic
strategies are needed for the suppression of cancer spread and
metastasis.
In 1930, Goerner et al.(28) first reported the inhibitory effect
of heparin against the growth of transplanted tumor tissues.
Subsequently, anticoagulant therapy with unfractionated hepa-
rin(29–31) or warfarin(32–34) has come to be indicated for several
types of cancers. Numerous subsequent studies confirmed that
anticoagulant agents improve the overall survival of cancer
patients.(28–33) Low molecular weight heparin is a fragmented
and fractionated heparin consisting of short polysaccharide
chains with anticoagulant activity.(35) The effect of LMWH on
the improvement of overall survival has also been shown in
various types of cancers.(36–38) Altinbas et al.(39) reported that
treatment with LMWH improved chemotherapy responsiveness
and overall survival in small cell lung cancer. Several
mechanisms other than anticoagulation have been proposed to
underlie the antitumor activity of LMWH.(39) Harvey et al.(40)
suggested that LMWH may have an antagonistic effect
on CXCR4 in breast cancer cells and thus inhibit tumor
cell metastasis. Our group reported that LMWH, dalteparin
obtained by deaminative cleavage of heparin with nitrous acid,
had an antagonistic effect on RAGE.(41) Moreover, we reported
its preventive and therapeutic effects on diabetic nephropathy
in vivo.(41) On the basis of these findings, we hypothesized that
the antitumor activity of LMWH, at least in part, depends on
the competitive inhibition of RAGE–ligand interaction.
In this study, we investigated whether LMWH could inhibit
tumor cell proliferation, migration, invasion, and distant metas-
tasis by blocking the RAGE axis in vitro and in vivo using
wild-type RAGE- and dominant negative RAGE-overexpress-
ing human fibrosarcoma HT1080 cell lines.
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Materials and Methods
Cell line. The HT1080 human fibrosarcoma cells (ATCC,
Rockville, MD, USA) were transfected with a plasmid
containing human full-length RAGE cDNA, cytoplasmic
domain-deleted dominant negative RAGE cDNA, or the vector
alone, as described previously.(42,43) Stably transformed clones
were selected, and the expression of RAGE variants were
verified by Western blotting. The resultant clones were
classified as HT1080RAGE, HT1080dnRAGE, and HT1080mock
cells. These cells were maintained in RPMI-1640 medium
supplemented with 10% FBS, 100 U ⁄mL penicillin and
100 lg ⁄mL streptomycin in the presence of G418 (Geneticin,
750 lg ⁄mL; Roche Applied Science, Mannheim, Germany).
Nuclear factor-jB luciferase assay. Rat C6 glioma cells were
used for this assay according to the previously described
method.(38,39) Briefly, cells were transfected with plasmid vec-
tors encoding luciferase cDNA under the control of an enhan-
cer element containing five NFjB binding sites (pNFjB-Luc;
Stratagene Corp., La Jolla, CA, USA) and human full-length
RAGE cDNA. Stably transfected clones were selected and
used for the subsequent assay. After a 24-h preincubation in
DMEM supplemented with 0.1% FBS, the cells were stimu-
lated by 1.0 lg ⁄mL HMGB1 (Sigma-Aldrich, St. Louis, MO,
USA) with or without 0.1 and 1.0 IU ⁄mL LMWH (dalteparin
sodium [Fragmin]; Pfizer Inc., New York, NY, USA) for 4 h.
The luciferase activity was determined using the Luciferase
Assay System (Promega Corp., Madison, WI, USA) and mea-
sured in a luminometer (Fluoroscan Ascent FL; Labsystems,
Helsinki, Finland).
Measurement of NFjB ⁄p65, Rac1, and Cdc42 activities. To
detect p65 nuclear translocation, NFjB ⁄p65 ActiveELISA (Im-
genex, San Diego, CA, USA) was used according to the manu-
facturer’s protocol. The G-LISA Rac1 and Cdc42 Activation
Assay Biochem kits (Cytoskeleton, Denver, CO, USA) were
used for the measurement of Rac1 and Cdc42 activities,
respectively.
Western blot analysis. Western blot analysis was carried out
as previously described.(43) Briefly, proteins (40 lg) in the cell
lysates were boiled and resolved by SDS-PAGE (12.5%) then
transferred onto a PVDF membrane (Millipore Corp., Bedford,
MA, USA). The membranes were incubated with a polyclonal
anti-RAGE antibody and IRDye 680 anti-rabbit IgG, and im-
munoreacted bands were visualized using the Odyssey Infrared
Imaging system (LI-COR Biotechnology, Lincoln, NE, USA).
Flow cytometry. The expression of RAGE on the cell surface
of transformed HT1080 human fibrosarcoma cells was
confirmed by flow cytometry. Cells were stained with anti-
human RAGE antibody (R&D Systems, Minneapolis, MN,
USA) and with anti-mouse IgG-Alexa Fluor 488 (Molecular
Probes Inc., Eugene, OR, USA) (15 min at 4°C in the dark)
then resuspended in 200 lL staining buffer containing 0.2 lg
⁄mL propidium iodide (Sigma–Aldrich), filtered through a 100-
lm mesh, and analyzed with FACS AriaII (BD Biosciences,
San Jose, CA, USA). Data were transferred and reanalyzed
with FlowJo software (Tree Star, San Carlos, CA, USA).
Confocal microscopy. The expression patterns of RAGE and
HMGB1 in HT1080 were assessed under immunofluorescence
confocal microscopy. HT1080 cells were cultured on Lab-Tek
chamber slides (Nalge Nunc International, Naperville, IL,
USA), fixed with PBS containing 4% paraformaldehyde for
10 min and made permeable by incubating them with PBS
containing 0.2% Triton X-100 for 5 min. After blocking with
PBS containing 2% BSA for 30 min, cells were exposed to
goat polyclonal antibody against the V domain of RAGE
(1:800 dilution; Millipore) or against HMGB1 (1:50 dilution;
Santa Cruz Biotechnology, Santa Cruz, CA, USA).(44) Donkey
anti-goat IgG labeled with Alexa Fluor 556 (1:200 dilution;
Molecular Probes) was used as the secondary antibody for the
detection of RAGE or HMGB1; DAPI (Vectashield; Vector
Laboratories Inc., Burlingame, CA, USA) was used for nuclear
staining. The images were obtained with a fluorescence micro-
scope (BZ-9000; Keyence, Osaka, Japan).
High mobility group box 1 ELISA. The HMGB1 levels in cell
culture media were measured with a Shino-Test ELISA system
(Tokyo, Japan).(8)
Cell proliferation assay. The HT1080RAGE, HT1080dnRAGE,
and HT1080mock cells were seeded at a density of 1 9 104
cells ⁄well in a six-well plate (BD Biosciences). After incuba-
tion for 12 h, culture medium was replaced with fresh RPMI-
1640 medium supplemented with 10% FBS with or without
1.0 lg ⁄mL HMGB1 and ⁄or 1 IU ⁄mL LMWH. After additional
incubation for 24 h, cell proliferation was assessed by the
MTT method,(45) and the total viable cell number was counted
on a hemocytometer using the dye exclusion method with
0.2% Trypan blue (Invitrogen, Carlsbad, CA, USA) at 0, 12,
24, 48, and 72 h.
Cell migration assay. Cell migration was evaluated by
a monolayer denudation assay as described previously.(46)
Briefly, HT1080RAGE, HT1080dnRAGE, and HT1080mock cells
were seeded at a density of 2 9 105 cells ⁄well and were
grown to confluence in a 6-well plate. Cells were then
wounded by denuding a strip of the monolayer approximately
1 mm in width with a 200 lL pipette tip. Cells were washed
twice with serum-free RPMI-1640 medium then further incu-
bated in RPMI-1640 ⁄10% FBS with or without 1.0 lg ⁄mL
HMGB1 and ⁄or 1 IU ⁄mL LMWH. The rate of wound closure
was assessed in six separate fields after 24 h of the denudation
using Image J software (http://rsb.info.nih.gov/ij/index.html).
Cell invasion assay. Matrigel-coated porous filters (8-lm
pore size) in a 12-well format were used as a barrier in a
Boyden chamber(39) to assess the extent of the invasion by
HT1080RAGE, HT1080dnRAGE, and HT1080mock cells. Cells
were plated into the inner chamber at an initial density of
2 9 105 with RPMI-1640 ⁄0.1% BSA. The outer chamber was
supplied with an addition of fibronectin (500 lg ⁄mL). After
24 h incubation in the presence or absence of HMGB1
(1.0 lg ⁄mL) and ⁄or LMWH (1 IU ⁄mL) into both the inner
and outer chambers, membranes were cut and removed from
their insert housings. The filter membrane was fixed in 4%
paraformaldehyde after the removal of non-invasive cells from
the upper chamber using a cotton swab. The bottom surface
containing the invasive cells was stained with crystal violet,
and the invasive cells were counted in six separate fields using
an optimal microscope at 9100 magnification.
In vivo tumorigenesis and metastasis assays. Six-week-old
female athymic nude mice (BALB ⁄ c-nu/nu; Japan SLC Co.,
Shizuoka, Japan) were used for the tumorigenesis and metasta-
sis assays. HT1080RAGE, HT1080dnRAGE, and HT1080mockcells
(each at 1 9 106 cells) were implanted s.c. into the back of
the mice. For the LMWH treatment group, 80 IU LMWH was
injected s.c. daily 24 h after the tumor cell implantation. The
tumor size of the xenografts was measured weekly with cali-
pers, and the tumor volume was estimated with the formula
(width 9 length2) ⁄2 until 28 days after the implantation. For
the metastasis assay, HT1080RAGE, HT1080dnRAGE, and
HT1080mock cells (1 9 106 cells in 0.2 mL PBS) were injected
into the tail vein. For the LMWH treatment group, 80 IU
LMWH were also injected s.c. daily. Twenty-eight days after
the tumor cell injection, mice were killed and the lungs were
resected. The colony number of metastatic tumor in the bilat-
eral lung was counted. Animals were treated in accordance
with the Fundamental Guidelines for the Proper Conduct of
Animal Experiments and Related Activities in Academic
Research Institutions under the jurisdiction of the Ministry of
Education, Culture, Sports, Science and Technology of Japan.
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Animal experiments were approved by the Committee on
Animal Experimentation of Kanazawa University (Kanazawa,
Japan).
Statistical analyses. Analyses were carried out using Stat
View (version 5.0; SAS Institute, Cary, NC, USA). One-way
ANOVA and Fischer’s exact tests were used when mean
differences were identified between the groups. For all compar-
isons, values of P < 0.05 were defined as significant.
Results
Low molecular weight heparin inhibition of HMGB1–RAGE-
induced NFjB activation. We first examined whether LMWH
could block HMGB1-induced NFjB activation in a C6 glioma
cell line. The stable cell line expressing RAGE protein
was previously established and useful for assaying
RAGE-dependent NFjB activity.(41) The addition of HMGB1
at a concentration of 1 lg ⁄mL significantly increased the
NFjB promoter-driven luciferase activity when compared to
the non-treated control (Fig. 1). The increased NFjB activa-
tion by HMGB1 was significantly attenuated by treatment with
1.0 IU ⁄mL LMWH (Fig. 1). This is consistent with the antag-
onistic effect of LMWH on the AGE–RAGE axis, shown in
our previous report.(41)
Effects of LMWH on cell proliferation, migration, and invasion
in vitro. To investigate RAGE-dependency of the malignant
phenotypes, we next generated three different types of
transformed HT1080 human fibrosarcoma cells, HT1080RAGE,
HT1080dnRAGE, and HT1080mock cells. The expression of
RAGE or dnRAGE was checked by Western blotting (Fig. 2a),
and cell surface RAGE expression was evaluated by flow
cytometry (Fig. 2b). There were markedly high expression lev-
els of RAGE immunoreactivity in HT1080RAGE and
HT1080dnRAGE cells; HT1080mock cells displayed a very low
expression level of endogenous RAGE proteins (Fig. 2a,b).
Immunofluorescent microscopy analysis revealed a nuclear
staining of HMGB1 and a faint and diffuse cytoplasmic stain-
ing of RAGE expression in HT1080 mock cells (Fig. 2c).
Secreted HMGB1 levels were not different among the three
groups (Fig. 2d). To confirm the effects of LMWH on
HMGB1-induced and RAGE-dependent cellular signaling such
as NFjB, Rac1, and Cdc42, we cultured the three HT1080 cell
lines under serum-deprived conditions. Obtained data clearly
shows that HMGB1 could significantly induced NFjB, Rac1
and Cdc42 activities only in HT1080RAGE cells and the induc-
tions were completely canceled by the treatment of LMWH
(Fig. 2e–g). We then compared the malignant phenotypes of
these cells in vitro. Cell proliferation of HT1080RAGE cells
was significantly higher than that of HT1080mock cells at every
time point (Fig. 3a). In contrast, the cell number of
HT1080dnRAGE was significantly lower than that of
HT1080mock cells (Fig. 3a). Although it was hard to see a
stimulation of cell proliferation by the addition of HMGB1
under RPMI-1640 media with 10% FBS, cell counting and
MTT assays also revealed the highest rate of cell proliferation
in HT1080RAGE cells (Fig. 3b,c). We speculated that HMGB1
in the complete culture media sufficiently stimulated the cell
proliferation in an autocrine and a paracrine fashion, as an
addition of neutralizing antibody against HMGB1 was found
to significantly inhibit the cell proliferation (data not shown).
In the cell migration assay, the rate of wound closure was
significantly higher in HT1080RAGE cells than HT1080mock
or HT1080dnRAGE cells at 24 h after a monolayer denudation
(Fig. 4). The Boyden chamber cell invasion assay revealed that
HT1080RAGE cells had the highest number of invasive cells
among the groups; the invasive cell number of HT1080dnRAGE
cells was significantly lower than that of HT1080mock cells
(Fig. 5). Overexpression of RAGE thus exacerbated, but over-
expression of dnRAGE attenuated, the malignancy-related
cellular phenotype in HT1080 fibrosarcoma cells.
The effects of LMWH on the RAGE-mediated cell prolifera-
tion, migration, and invasion of HT1080 cells were then exam-
ined. The LMWH significantly inhibited cell proliferation and
migration in HT1080RAGE cells, but not in HT1080mock or
HT1080dnRAGE cells (Fig. 3b,c, Fig. 4). The treatment with
LMWH also significantly blocked the RAGE-overexpression-
induced cell invasion in HT1080RAGE cells, but not in
HT1080mock or HT1080dnRAGE cells (Fig. 5).
Effects of LMWH on tumorigenesis and metastasis in vivo.
After obtaining positive results for LMWH in vitro, we then
examined the in vivo effects of LMWH on tumorigenesis and
metastasis using nude mice. After 28 days of tumor cell
implantation in the back, the mean tumor volume of
HT1080RAGE cells was significantly larger than that of
HT1080mock cells (Fig. 6a). With HT1080dnRAGE cells, there
was a tendency of suppression of the increase in the tumor
volume (Fig. 6a). Treatment with LMWH apparently inhibited
the local tumor growth of HT1080RAGE cells compared to
PBS-treated controls during the observation period of
4 weeks (Fig. 6b). However, LMWH did not show any inhib-
itory effects on the local tumor growth in either HT1080mock
Fig. 1. Luciferase assay for nuclear factor jB activation. Cells were
stimulated by 1.0 lg ⁄ mL high mobility group box 1 (HMGB1) with or
without 0.1 and 1.0 IU ⁄ mL low molecular weight heparin (LMWH;
dalteparin sodium) for 4 h. The luciferase activity was measured. Val-
ues represent the mean  SE (n = 4).
Fig. 2. (Figure on next page) Expression of receptor for advanced glycation end products (RAGE) and high mobility group box 1 (HMGB1) and
HMGB1-mediated RAGE signaling. (a) RAGE expression was examined by Western blotting. (b) Cell surface RAGE was examined by flow cytometry. (c)
Expression patterns of RAGE and HMGB1 in mock-transfected control (HT1080mock) cells were determined by immunofluorescence confocal microscopy
(a,b, Alexa Fluor 556; c,d, DAPI). Magnification, 940. Scale bar = 50 lm. (d) HMGB1 levels in cell culture media. Each cell was cultured in serum-free
media for 24 h and the HMGB1 concentration was then assayed with ELISA. (e–g) Nuclear factor-jB ⁄p65, Rac1, and Cdc42 activities. Each cell was cul-
tured in 0.1% serum media. C, non-treated control; H, 0.1 lg ⁄ mL HMGB1; H+L, 0.1 lg ⁄mL HMGB1 and 1.0 IU ⁄ mL LMWH; HT1080dnRAGE, RAGE domi-
nant-negative, intracellular tail-deleted RAGE-overexpressing fibrosarcoma cells; HT1080RAGE, human full-length RAGE-overexpressing fibrosarcoma
cells. Values represent the mean  SE (n = 3).
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or HT1080dnRAGE cells (Fig. 6c,d). We then assessed tumor
cell metastasis to the lung. The number of tumor colonies in
the lung significantly increased in the HT1080RAGE cells
compared to HT1080mock cells after 28 days of tail vein
injection of the cells (Fig. 6e). The number was found to be
the lowest in the HT1080dnRAGE cells (Fig. 6f). Moreover,
the treatment of LMWH significantly suppressed the lung
metastasis of HT1080RAGE cells when compared to the
PBS-treated control group (Fig. 6f). During the experimental
periods, we could not find any obvious side-effects of
LMWH on nude mice.
Discussion
The interaction between HMGB1 and RAGE has been reported
to contribute to tumor cell proliferation and invasiveness.(10,18)
Clinicohistopathogical studies showed the expression of RAGE




Fig. 3. Cell proliferation. (a) Viable cell number was
calculated at 0, 12, 24, 48, and 72 h after the seeding
of human full-length receptor for advanced glycation
end products (RAGE)-overexpressing (HT1080RAGE),
RAGE dominant-negative, intracellular tail-deleted
RAGE-overexpressing (HT1080dnRAGE), and mock-
transfected control (HT1080mock) fibrosarcoma cells.
Values represent the mean  SE (n = 5). (b) Viable
cell number was calculated at 72 h after cell seeding
and (c) MTT assay was carried out under 10% serum
media. C, non-treated control; H, 0.1 lg ⁄ mL high
mobility group box 1 (HMGB1); H+L, 0.1 lg ⁄mL
HMGB1 and 1.0 IU ⁄mL low molecular weight heparin.
Values represent the mean  SE (n = 5).
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(a)
(b)
Fig. 4. Cell migration. Scratch wound assay was carried out using human full-length receptor for advanced glycation end products (RAGE)-overexpressing
(HT1080RAGE), RAGE dominant-negative, intracellular tail-deleted RAGE-overexpressing (HT1080dnRAGE), and mock-transfected control (HT1080mock)
fibrosarcoma cells under 10% serum media. The rectangle composed of black lines indicates the area of the initial scratch wound. The filled wound
area was calculated. Scale bar = 200 lm. C, non-treated control; H, 0.1 lg ⁄ mL high mobility group box 1 (HMGB1); H+L, 0.1 lg ⁄ mL HMGB1 and
1.0 IU ⁄ mL low molecular weight heparin. Values represent the mean  SE (n = 5).
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tumors, such as lung,(20) breast,(20) and prostate cancers,(21,22)
as well as malignant melanoma.(20) The present study clearly
indicated that the overexpression of human full-length signal-
transducing RAGE in HT1080 cells aggravated the cellular
phenotype in terms of proliferation, migration, and invasion
in vitro, and tumorigenesis and distant metastasis in vivo
(Figs 3–6). In contrast, forced expression of intracellular
domain-deleted dominant-negative RAGE significantly inhib-
ited cell proliferation, invasion, and metastasis (Figs 3–6).
These results indicate that RAGE is a key regulator of the
malignant phenotype in tumor cells, which is in agreement
with previous findings using N18 neuroblastoma, B16-F1 mel-
anoma, and C6 glioma cells.(11,18) Therefore, RAGE is a prom-
ising therapeutic target in tumor malignancy. For targeting
RAGE, Huttunen et al. used a C-terminal motif in the form of
an amphoterin ⁄HMGB1 peptide (amino acids 150–183), which
was shown to bind to RAGE and efficiently inhibit the inva-
sive migration of HT1080 cells.(18) Taguchi et al. reported that
the blockade of HMGB1–RAGE using soluble RAGE
decreased C6 glioma cell tumor growth and metastasis.(11) Our
group showed that the LMWH dalteparin had an antagonistic
effect on RAGE and attenuated the development and progres-
sion of diabetic nephropathy.(41) Subsequent to our previous
report, it was reported that 2-O,3-O-desulfated heparin, another
low molecular weight anticoagulant heparin derivative pro-
duced from cold alkaline hydrolysis of unfractionated heparin,
had a similar antagonistic action against RAGE.(47) Accord-
ingly, we decided to use dalteparin for tumor treatment and to
investigate whether LMWH has an antitumor effect through a
blockade of RAGE within the therapeutic range of the plasma
LMWH concentrations.
The correlation between cancer and thrombosis is well doc-
umented.(28–34) Heparins represent the first choice for the pre-
vention and treatment of venous thromboembolism. In
particular, LMWH possesses certain pharmacokinetic
advantages over unfractionated heparin, including a longer
half-life, better bioavailability, and lower binding to plasma
proteins. The results of preclinical and clinical studies have
suggested that LMWH might inhibit cell growth, cell inva-
sion, and angiogenesis in cancer, indicating its anticoagulant
and direct antitumor effects.(35–38) Moreover, several clinical
trials have shown an improvement in overall survival by
LMWH treatment in cancer patients, even in those at
advanced stage of disease.(36–39) The efficacy of LMWH treat-
ment has been reported in various histological types of malig-
nancies including lung,(39) breast,(37) gastric,(37) hepatic,(37)
colorectal,(37) pancreatic,(48) and prostatic cancers.(37)
In this study, we report for the first time that LMWH sig-
nificantly inhibits the cell proliferation, migration, invasion,
local tumor growth, and lung metastasis of HT1080 fibrosar-
coma cells through a blockade of the RAGE axis (Figs 3–6).
The in vitro and in vivo data for the most part clearly indi-
cate that the antagonistic effect of LMWH against RAGE
inhibit tumor cell growth, migration, invasion, and distant
metastasis (Figs 3–6). Concerning a possible additional direct
antitumor effect of LMWH, Harvey et al. suggested an
(a)
(b)
Fig. 5. Cell invasion. Matrigel cell invasion assay was
carried out using human full-length receptor for
advanced glycation end products (RAGE)-overexpressing
(HT1080RAGE), RAGE dominant-negative, intracellular
tail-deleted RAGE-overexpressing (HT1080dnRAGE), and
mock-transfected control (HT1080mock) fibrosarcoma
cells under 10% serum media. Scale bar = 200 lm.
C, non-treated control; H, 0.1 lg ⁄mL high mobility
group box 1 (HMGB1); H+L, 0.1 lg ⁄mL HMGB1 and
1.0 IU ⁄mL low molecular weight heparin. Values
represent the mean  SE (n = 5).
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antagonistic effect of LMWH on CXCR4 in breast cancer
cell metastasis.(40) The heterocomplex between HMGB1 and
CXCL12 was reported to be involved in mononuclear cell
recruitment through CXCR4,(49) and Ma et al. also reported
that LMWH inhibited the formation of hepatic metastasis of
colon cancer cells by disrupting the interaction of CXCR4
and CXCL12.(50) Although LMWH is a multifunctional bio-
logical molecule, and other yet unknown functions of
LMWH may be discovered, LMWH is already suggested to
be a useful drug for tumor therapy, especially as a novel
adjuvant cancer treatment. To assess the efficacy of LMWH
for the treatment of bone and soft tissue sarcoma, the
expression of RAGE should be assessed. We found a potent
expression of RAGE in certain types of sarcomas (data not
shown). Large prospective cohort studies will be required to
draw a conclusion about the efficacy of LMWH and to eval-
uate the effect of clinical applications in patients with vari-
ous cancers.
In conclusion, this study has shown that the LMWH daltep-




Fig. 6. In vivo tumorigenesis assay. (a) Human full-length receptor for advanced glycation end products (RAGE)-overexpressing (HT1080RAGE),
RAGE dominant-negative, intracellular tail-deleted RAGE-overexpressing (HT1080dnRAGE), and mock-transfected control (HT1080mock) fibrosarcoma
cells were implanted into the back of athymic nude mice (BALB ⁄ c-nu/nu) at a density of 1 9 106 cells. The local tumor volume was calculated at
0, 1, 2, 3, and 4 weeks after the implantation. Values represent the mean  SE (n = 5). (b) Low molecular weight heparin (LMWH) treatment
significantly blocked the local tumor growth of HT1080RAGE cells. Control, mice receiving a daily injection of PBS; LMWH, mice receiving a daily
injection of 80 IU LMWH. Values represent the mean  SE (n = 5). Treatment with LMWH did not affect the local tumor growth of HT1080mock
cells (c) or HT1080dnRAGE cells (d). Control, PBS injection; LMWH, LMWH injection. Values represent the mean  SE (n = 5). In vivo lung metastasis
assay (e). HT1080RAGE, HT1080dnRAGE and HT1080mock cells (1 9 106 cells) were injected into the tail vein of athymic nude mice (BALB ⁄ c-nu/nu).
The number of lung colonies was assessed (f). C, control mice receiving daily injection of PBS; LMWH, mice receiving daily injection of 80 IU
LMWH. Values represent the mean  SE (n = 5).
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contributing to the inhibition of tumor cell growth, migration,
invasion, and distant metastasis in human fibrosarcoma cells.
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HT1080RAGE human full-length RAGE-overexpressing human
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